Thursday 16 October, 2025
Introduction: Diabetes mellitus (DM) is a chronic metabolic disorder which contributes to many healthcare related problems globally and is more…
Read moreAbstracts
Current and future applications of circulating tumor DNA (ctDNA) to oncology drug development
Thursday 16 October, 2025
Objectives: The objectives of the presentation are Describe the assays used to measure ctDNA. Discuss the applications of ctDNA in…
Read moreDeveloping a PBPK/PD/Tox Modelling Framework for NANOBODY® Drug Conjugates
Thursday 16 October, 2025
Introduction: Sanofi R&D, Ghent, Belgium has initiated a project towards the rational design of NANOBODY®-Drug Conjugates (NDCs). NDCs are molecular…
Read moreBuilding a physiologically-based pharmacokinetic model for a carcinogenic food contaminant aflatoxin B1
Thursday 16 October, 2025
Objectives: Building a PBPK-model for AFB1 Validation of the developed substrate file with human in vivo data Application of the…
Read moreAn Artificial Intelligence Framework for Optimal Drug Design
Thursday 16 October, 2025
Objectives: To develop an end-to-end in silico framework for optimizing the exposure, safety, and efficacy of drugs. To provide a proof-of-concept…
Read moreMechanistic PKPD modelling of targeted protein degradation to improve compound selection in drug discovery and translation to the clinic
Thursday 16 October, 2025
Introduction: Protein degradation via PROTACs (proteolysis targeting chimeras) or molecular glue degraders is an attractive new therapeutic approach. It provides…
Read moreA Pharmacometric approach for opioid use disorder in Puerto Rico: A research agenda to individualize buprenorphine pharmacotherapy.
Thursday 16 October, 2025
Objectives: The objective of this poster is to present our strategy for transforming the current standard of care for opioid use…
Read moreExternal Validation of Population PK and PD Models for Characterizing the Impact of CYP2C9 and VKORC1 Genotypes in the Management of Warfarin Therapy in Caribbean Hispanic Patients.
Thursday 16 October, 2025
Objectives: The role of genetic polymorphisms in partially characterizing interindividual variability (IIV) in warfarin exposure and clinical response has been…
Read moreA Bayesian (P)K-TTE model to support early dose escalation decisions in phase 1 Oncology studies
Thursday 16 October, 2025
Introduction The design of phase I trials in oncology follows mainly a dose-escalation (DE) design monitoring dose limiting toxicity (DLT)…
Read moreOptimizing infusion rates for N,N-dimethyltryptamine based on either a continuous variable model or a bounded integer model
Thursday 16 October, 2025
Introduction/Objectives: N,N-dimethyltryptamine (DMT) is a psychedelic compound that is currently being studied as a treatment option in a number of…
Read more